A Phase 1/2a Multicenter Open-Label First in Human Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Antitumor Activity of DB-1303 in Patients with Advanced/Metastatic Solid Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Her2-positive Advanced Solid Tumor
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Female
  • Other Inclusion Criteria:
    1. Participant should have a pathologically documented HER2-positive or HER2-expressing advanced/unresectable, recurrent, or metastatic malignant solid tumor that is refractory to or intolerable with standard treatment, or for which no standard treatment

You may not be eligible for this study if the following are true:

  • 1. History of symptomatic CHF (New York Heart Association [NYHA] classes II-IV) or serious cardiac arrhythmia requiring treatment. 2. History of myocardial infarction or unstable angina within 6 months before Day 1. 3. Average QTcF > 450 ms in male


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.